The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4000 participants.
Also called NCT02575092
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 4,000 participants
- Sponsor
- Fuling Central Hospital of Chongqing City
- Registry
-
NCT02575092
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02575092. Randomized; double masking; primary purpose treatment. Start 2015-11-01 (actual); primary completion 2019-02-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment
- Acronym
- CONTRAST-CADT
- Condition
- Homocysteine
- Condition
- Coronary Disease
- Condition
- Angioplasty,Balloon,Coronary
- Condition
- Contrast Media
- Condition
- Nephropathy
- Condition
- Hypertension
- Intervention (Drug)
- Enalapril Maleate Tablets(as the program-based antihypertension)
- Intervention (Drug)
- Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Fuling Central Hospital of Chongqing City
Record details
- Record id
cardio:ct-nct02575092- Content hash
b27eef4b6a7f608590c3b6d12441480deecfd2191c7aa7a2407245556cc1f0d5